Mass. Movers

Vertex reports progress on CF treatment

The biotech’s new treatment may help thousands.

The Boston Globe/File 2006

The biotech’s new treatment may help thousands.

Vertex Pharmaceuticals’ shares soared after the Cambridge biotech released positive clinical data on an experimental treatment for cystic fibrosis. Vertex said a midstage study of its VX-661 drug candidate in combination with its approved cystic fibrosis drug Kalydeco “showed statistically significant improvements in lung function” among adults with two copies of a common cystic fibrosis regulator gene mutation. The disease causes mucus to build up in the lungs and digestive tract.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of